W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

News

The Meeting of the Transparency Council No. 31/2022 of 11.08.2022

more...

The Meeting of the Tariffs Council No. 19/2022 of 11.08.2022

more...

Opinion of the President – Breast cancer prevention programme – ultrasound examination for women aged 30 to 49 from the town of Sieradz

more...

The Meeting of the Transparency Council No. 30/2022 of 01.08.2022.

more...

Recommendation of the President – Yervoy (ipilimumab) in combination with Opdivo (nivolumab)

more...

Recommendation of the President – Opdivo (nivolumab) in combination with Yervoy (ipilimumab)

more...

Opinion of the Transparency Council – health policy programme on therapeutic rehabilitation (town of Żyrardów)

more...

Opinion of the Transparency Council – health policy programme on breast cancer prevention (town of Sieradz)

more...

Opinion of the Transparency Council – changes to the drug programme B.61

more...

Opinion of the Transparency Council – active substance ipratropii bromidum

more...

Opinion of the Transparency Council – active substances fenoteroli hydrobromidum + ipratropii bromidum

more...

Opinion of the Transparency Council – active substance prednisone

more...

Opinion of the Transparency Council – active substances amiloridum + hydrochlorothiazidum

more...

Opinion of the Transparency Council – health policy programme on medical rehabilitation (Municipality of Mielno)

more...

Opinion of the Transparency Council – health policy programme on detection of vision defects (Municipality of Chociwel)

more...

Opinion of the Transparency Council – health policy programme on detection of vision defects (town of Będzin)

more...

Position of the Transparency Council – Rezurock (belumosudil)

more...

Position of the Transparency Council – Yervoy (ipilimumab)

more...

Position of the Transparency Council – Opdivo (nivolumab)

more...

Opinion of the Transparency Council – combining drug programmes B.29 and B.46

more...

Position of the Transparency Council – non gamma 2 capsule amalgam

more...

The Meeting of the Transparency Council No. 29/2022 of 25.07.2022

more...

Communication on the meeting of the Tariff Council on 14.07.2022

more...

The Meeting of the Tariffs Council No. 18/2022 of 28.07.2022

more...